Nov 25 – Swiss dental implant maker Straumann (STMN.S) said on Tuesday that regulatory and pricing changes in China could reshape competition in the dental implant sector. These shifts are likely to benefit new rivals emerging both in China and other regions.
Most of the competition in China currently comes from smaller companies. CEO Guillaume Daniellot said that no strong local challenger has yet appeared in the market. He noted that Chinese companies “have not been able to invest a lot in innovation, go-to-market strategies, or education.”
However, changes in China’s procurement rules may alter this dynamic. Since 2023, dental implants in China have been subject to volume-based procurement. This system could favor local manufacturers. The pricing for the next procurement round, scheduled for 2026, has not yet been announced.
Straumann is also monitoring similar trends in other regions. Daniellot highlighted ongoing discussions about pricing frameworks and local manufacturing in countries including India and Saudi Arabia. The company is responding proactively by expanding its local implant production in China. As part of this strategy, it is moving 250 jobs from its Villeret site in Switzerland to China, a plan first announced in June.
The group reaffirmed its long-term financial goals. It aims for average annual organic revenue growth of 10% through 2030.
Straumann also targets a 40 to 50 basis point increase in its operating profit margin over the same period. Its previous margin target had been set between 25% and 30%, a range that the new goal continues to fit when compared to the 2024 margin of 26%. These projections assume that foreign exchange rates remain constant from 2026 to 2030.
Partnerships with dental service organizations remain a central part of Straumann’s growth strategy. These organizations account for roughly 30% of the global dentistry market. They help drive patient traffic and invest heavily in advertising for high-end treatments, according to Daniellot.
Demographic trends also support the company’s expansion plans. Daniellot pointed to ageing populations in countries such as China, Japan, Germany, and Switzerland. He also highlighted the untapped potential in emerging markets. “There are 220 million patients per year who can afford implant treatments and have missing teeth. Yet only 17 million receive treatment annually,” he said.
Straumann stressed that it can achieve its 2030 growth ambitions without relying on new acquisitions. The company’s focus on innovation, local manufacturing, and strategic partnerships is expected to drive expansion even amid evolving global market conditions.
With a combination of regulatory awareness, investment in local production, and demographic tailwinds, Straumann appears well-positioned to navigate the changing dental implant landscape while maintaining strong growth and profitability targets through the next decade.